Physician profile
Bernard P Sweeney
NPI 1417907817
$1,924.23
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $710 · 2021: $29.30 · 2022: $122 · 2023: $67.87 · 2024: $84.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $831.00 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $336.45 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.54 | 2019-2021 | |
| Lilly USA, LLC | $121.51 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $72.28 | 2019-2020 | |
| Pfizer INC. | $57.90 | 2019 | |
| Amgen INC. | $56.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $53.60 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.94 | 2019-2020 | |
| Amarin Pharma, INC. | $39.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.04 | 2019 | |
| Astellas Pharma US INC | $34.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.62 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.65 | 2020 | |
| Eisai INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.